Sorafenib Completed Phase 2 Trials for Recurrent Glioblastoma Multiforme Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00597493Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM